Nykode Therapeutics Share Price
Stocks
VACC
NO0010714785
Biotechnology & Medical Research
OTC Markets Traded|
Real-time
Oslo Bors
12:04:18 27/08/2026 BST
|
5-day change | 1st Jan Change | ||
| 4.800 NOK | +4.35% |
|
+17.07% | +99.00% |
| 08-20 | Nykode Therapeutics Wins New US Patent for Neoantigen-based Cancer Vaccine | MT |
| 08-06 | Nykode Therapeutics Asa Announces Appointment of Jakob Helding Rasmussen as Chief Technology Officer | CI |
| Market Cap | 1.5B 161M 138M 129M 118M 223M 15.31B 224M 1.53B 593M 7.72B 603M 590M 25.59B | P/E 2026 * |
-7.08x | P/E 2027 * | -50x |
|---|---|---|---|---|---|
| Enterprise Value | 1.01B 108M 93.07M 87.36M 79.78M 151M 10.34B 151M 1.03B 401M 5.22B 407M 398M 17.28B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | 5.66x |
| Free-Float |
56.4% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript : Nykode Therapeutics
| 1 day | +4.35% | ||
| 1 week | +17.07% | ||
| Current month | +42.01% | ||
| 1 month | +49.30% | ||
| 3 months | +52.62% | ||
| 6 months | +65.86% | ||
| Current year | +99.00% |
| 1 week | 4.1 |  | 5.2 |
| 1 month | 3.08 | | 5.2 |
| Current year | 2.21 | | 5.2 |
| 1 year | 1.44 | | 5.2 |
| 3 years | 1.44 | | 30.18 |
| 5 years | 1.44 | | 85.3 |
| 10 years | 1.44 | | 93 |
| Manager | Title | Age | Since |
|---|---|---|---|
Michael Engsig
CEO | Chief Executive Officer | 54 | 31/12/2018 |
| President | 49 | 31/12/2016 | |
Harald Gurvin
DFI | Director of Finance/CFO | 51 | 02/05/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 54 | - | |
Trygve Lauvdal
BRD | Director/Board Member | 57 | - |
Susanne Stuffers
CHM | Chairman | 45 | 22/04/2025 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 27/03/25 | Buy | Company | 3,000,000 | 0.9187% | ||
| 20/12/24 | Buy | Director | 100,000 | 0.0306% | ||
| 20/12/24 | Sell | Director | 100,000 | 0.0306% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +4.35% | +17.07% | +207.69% | -82.25% | 161M | |
| +3.31% | -3.70% | +61.03% | +103.64% | 70.42B | |
| +1.09% | +2.53% | +49.37% | +93.27% | 65.4B | |
| -1.31% | -0.50% | +7.41% | -4.29% | 28.28B | |
| -0.49% | +1.73% | +59.01% | +11.60% | 26.57B | |
| +0.40% | -4.80% | -5.89% | +469.55% | 27.16B | |
| +1.13% | +2.01% | +37.62% | -16.96% | 20.09B | |
| +1.02% | +6.43% | +269.42% | +420.34% | 20.61B | |
| +0.77% | -1.59% | +13.19% | +543.56% | 15.87B | |
| -1.09% | +3.14% | +46.32% | +155.12% | 13.9B | |
| Average | +0.92% | +0.37% | +74.52% | +169.36% | 28.85B | |
| Weighted average by Cap. | +1.07% | +0.72% | +56.65% | +157.50% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | 163M 17.42M 14.95M 14.04M 12.82M 24.19M 1.66B 24.31M 166M 64.37M 838M 65.42M 64M 2.78B |
| Net income | -209M -22.33M -19.16M -17.99M -16.43M -31.01M -2.13B -31.15M -213M -82.5M -1.07B -83.84M -82.02M -3.56B | -41.39M -4.42M -3.8M -3.56M -3.25M -6.14M -422M -6.17M -42.17M -16.34M -213M -16.61M -16.25M -705M |
| Net Debt | -488M -52.1M -44.72M -41.97M -38.34M -72.35M -4.97B -72.7M -497M -193M -2.51B -196M -191M -8.3B | -580M -62.01M -53.22M -49.95M -45.62M -86.1M -5.91B -86.52M -591M -229M -2.98B -233M -228M -9.88B |
| Date | Price | Change |
|---|---|---|
| 27/08/26 | NOK 4.800 | +4.35% |
| 26/08/26 | NOK 4.600 | -0.86% |
| 25/08/26 | NOK 4.640 | +1.75% |
| 24/08/26 | NOK 4.560 | +1.11% |
| 21/08/26 | NOK 4.510 | +10.00% |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- VACC Stock
Select your edition
All financial news and data tailored to specific country editions
